Glioblastoma in Children: A Single-Institution Experience
- Department of Radiation Oncology and Mallinkrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri (United States)
- Division of Pediatric Hematology and Oncology, Washington University School of Medicine, St. Louis, Missouri (United States)
- Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri (United States)
Purpose: Current treatment recommendations for pediatric glioblastoma include surgery, chemotherapy, and radiation therapy. However, even with this multispecialty approach, overall survival remains poor. To assess outcome and evaluate treatment-related prognostic factors, we retrospectively reviewed the experience at our institution. Methods and Materials: Twenty-four glioblastoma patients under the age of 21 were treated with radiation therapy with curative intent at Washington University, St. Louis, from 1970 to 2008. Patients underwent gross total resection, subtotal resection or biopsy alone. Fourteen (58%) of the patients received chemotherapy. All patients received radiation therapy. Radiation consisted of whole-brain radiation therapy in 7 (29%) patients with a median dose of 50.4 Gy. Seventeen (71%) patients received three-dimensional conformal radiation therapy with a median dose of 54 Gy. Results: Median follow-up was 12.5 months from diagnosis. One and 2-year overall survival rates were 57% and 32%, respectively. Median overall survival was 13.5 months. There were no differences in overall survival based on patients' age, race, gender, tumor location, radiation volume, radiation dose, or the use of chemotherapy. There was a significant improvement in overall survival for patients in whom gross total resection was achieved (p = 0.023). Three patients were alive 5 years after gross total resection, and 2 patients were alive at 10 and 24 years after diagnosis. Conclusions: Survival for children with glioblastoma remains poor. Data from this and other studies demonstrate the importance of achieving a gross total resection. Continued investigation into new treatment options is needed in an attempt to improve outcome for these patients.
- OSTI ID:
- 21587613
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 4 Vol. 80; ISSN IOBPD3; ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
MGMT Gene Promoter Methylation as a Potent Prognostic Factor in Glioblastoma Treated With Temozolomide-Based Chemoradiotherapy: A Single-Institution Study
Postoperative Treatment of Primary Glioblastoma Multiforme With Radiation and Concomitant Temozolomide in Elderly Patients
Related Subjects
AGE GROUPS
ANIMALS
BIOPSY
BODY
BRAIN
CENTRAL NERVOUS SYSTEM
CHEMOTHERAPY
CHILDREN
DIAGNOSIS
DIAGNOSTIC TECHNIQUES
DISEASES
DOSES
GLIOMAS
MAMMALS
MAN
MEDICINE
NEOPLASMS
NERVOUS SYSTEM
NERVOUS SYSTEM DISEASES
NUCLEAR MEDICINE
ORGANS
PEDIATRICS
PRIMATES
RADIATION DOSES
RADIOLOGY
RADIOTHERAPY
SURGERY
THERAPY
VERTEBRATES